CL2019002112A1 - Compuestos moduladores del receptor de hidrocarburos de arilo (ahr). - Google Patents

Compuestos moduladores del receptor de hidrocarburos de arilo (ahr).

Info

Publication number
CL2019002112A1
CL2019002112A1 CL2019002112A CL2019002112A CL2019002112A1 CL 2019002112 A1 CL2019002112 A1 CL 2019002112A1 CL 2019002112 A CL2019002112 A CL 2019002112A CL 2019002112 A CL2019002112 A CL 2019002112A CL 2019002112 A1 CL2019002112 A1 CL 2019002112A1
Authority
CL
Chile
Prior art keywords
ahr
aryl hydrocarbon
hydrocarbon receptor
modulating compounds
compounds
Prior art date
Application number
CL2019002112A
Other languages
English (en)
Inventor
Christoph Steeneck
Ulrich Deuschle
Michael Albers
Thomas Hoffmann
Original Assignee
Phenex Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phenex Pharmaceuticals Ag filed Critical Phenex Pharmaceuticals Ag
Publication of CL2019002112A1 publication Critical patent/CL2019002112A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS QUE PUEDEN ACTUAR COMO MODULADORES DEL RECEPTOR DE HIDROCARBUROS DE ARILO (AHR) Y, EN PARTICULAR, COMO ANTAGONISTAS DE AHR. LA INVENCIÓN ADEMÁS SE REFIERE AL USO DE LOS COMPUESTOS PARA EL TRATAMIENTO Y/O PROFILAXIS DE ENFERMEDADES Y/O CONDICIONES A TRAVÉS DE LA UNIÓN DE DICHO RECEPTOR DE HIDROCARBUROS DE ARILO POR DICHOS COMPUESTOS.
CL2019002112A 2017-02-01 2019-07-29 Compuestos moduladores del receptor de hidrocarburos de arilo (ahr). CL2019002112A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17000157 2017-02-01

Publications (1)

Publication Number Publication Date
CL2019002112A1 true CL2019002112A1 (es) 2019-12-20

Family

ID=57960222

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019002112A CL2019002112A1 (es) 2017-02-01 2019-07-29 Compuestos moduladores del receptor de hidrocarburos de arilo (ahr).

Country Status (25)

Country Link
US (1) US11376241B2 (es)
EP (1) EP3577115B1 (es)
JP (1) JP2020505467A (es)
KR (1) KR20190113902A (es)
CN (1) CN110234650A (es)
AR (1) AR110790A1 (es)
AU (1) AU2018216955B2 (es)
BR (1) BR112019015704A2 (es)
CA (1) CA3051034A1 (es)
CL (1) CL2019002112A1 (es)
CO (1) CO2019007882A2 (es)
CR (1) CR20190393A (es)
CU (1) CU20190067A7 (es)
EA (1) EA201991600A1 (es)
EC (1) ECSP19055179A (es)
IL (1) IL268082A (es)
MX (1) MX2019008993A (es)
NI (1) NI201900075A (es)
PE (1) PE20191479A1 (es)
PH (1) PH12019550136A1 (es)
SG (1) SG11201906959RA (es)
TW (1) TWI674260B (es)
UA (1) UA122746C2 (es)
UY (1) UY37590A (es)
WO (1) WO2018141855A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI674260B (zh) 2017-02-01 2019-10-11 德商菲尼克斯製藥股份有限公司 芳基烴受體(AhR)調節劑化合物
TWI752155B (zh) 2017-02-01 2022-01-11 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物
CN111683950B (zh) 2018-02-06 2024-04-16 伊迪亚生物科学有限公司 AhR调节剂
WO2020021024A1 (en) * 2018-07-26 2020-01-30 Phenex Pharmaceuticals Ag Substituted bicyclic compounds as modulators of the aryl hydrocarbon receptor (ahr)
CN109813913B (zh) * 2019-01-31 2021-11-09 中国医学科学院肿瘤医院 芳烃受体(AhR)在预测免疫治疗效果中的应用
US20220281824A1 (en) * 2019-07-30 2022-09-08 Oregon State University Aryl hydrocarbon receptor activators
KR102351515B1 (ko) 2019-12-17 2022-01-14 (주)수파드엘릭사 아릴 탄화수소 수용체의 활성을 억제하는 폡타이드 및 이를 이용하는 화장료 조성물
EP4093739A1 (en) * 2020-01-23 2022-11-30 Phenex Pharmaceuticals AG Oxalamide substituted heterocyclic compounds as modulators of the aryl hydrocarbon receptor (ahr)
CN114181212B (zh) * 2020-09-15 2023-06-06 山东轩竹医药科技有限公司 哒嗪酮类AhR抑制剂
WO2022146920A1 (en) * 2020-12-28 2022-07-07 Celgene Corporation Heterocyclic compounds and their use for parasitic diseases
CN115572282A (zh) * 2021-07-05 2023-01-06 华东理工大学 含芳杂环结构的吡唑酰胺类化合物及其制备方法和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8225991A (en) 1990-07-31 1992-03-02 Teikoku Hormone Mfg. Co., Ltd. 2-phenylindole derivative
WO1998022457A1 (en) 1996-11-19 1998-05-28 Amgen Inc. Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents
WO2004024655A2 (en) 2002-09-12 2004-03-25 Avanir Pharmaceuticals Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation
US20050032869A1 (en) 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
EP1966199B1 (en) 2005-11-18 2010-10-20 F. Hoffmann-La Roche AG Azaindole-2-carboxamide derivatives
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
PL2488486T3 (pl) 2009-10-13 2020-01-31 Ligand Pharmaceuticals Inc. Małocząsteczkowe związki mimetyczne hematopoetycznego czynnika wzrostu i ich zastosowania
CA2776319C (en) * 2009-11-02 2018-01-02 Jiasheng Song Ite for cancer intervention and eradication
US20130338201A1 (en) * 2009-11-02 2013-12-19 Ahr Pharmaceuticals, Inc. Method of Cancer Treatment with 2-(1H-Indole-3-Carbonyl)-Thiazole-4-Carboxylic Acid Methyl Ester
DK2531501T3 (en) 2010-02-03 2014-02-24 Takeda Pharmaceutical APOPTOSESIGNALREGULERENDE KINASE 1 inhibitors
US8410117B2 (en) 2010-03-26 2013-04-02 Hoffmann-La Roche Inc. Imidazopyrimidine derivatives
TWI619713B (zh) 2010-04-21 2018-04-01 普雷辛肯公司 用於激酶調節的化合物和方法及其適應症
CN107648216B (zh) 2010-07-27 2021-03-30 波士顿大学管理委员会 作为新型癌症疗法的芳烃受体(AhR)调节剂
GB201104267D0 (en) * 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
MX2015004500A (es) 2012-10-17 2015-07-06 Hoffmann La Roche Derivados de 6-aminoindol como antagonistas del canal receptor de potencial transitorio (trp).
PL2935248T3 (pl) 2012-12-21 2018-07-31 Plexxikon Inc Związki i sposoby modulacji kinaz i wskazania dla nich
TWI674260B (zh) 2017-02-01 2019-10-11 德商菲尼克斯製藥股份有限公司 芳基烴受體(AhR)調節劑化合物
TWI752155B (zh) * 2017-02-01 2022-01-11 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物
TW201835070A (zh) 2017-02-21 2018-10-01 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物

Also Published As

Publication number Publication date
EP3577115A1 (en) 2019-12-11
AU2018216955B2 (en) 2020-09-17
UA122746C2 (uk) 2020-12-28
EP3577115B1 (en) 2020-12-02
ECSP19055179A (es) 2019-08-30
CU20190067A7 (es) 2020-03-04
JP2020505467A (ja) 2020-02-20
CN110234650A (zh) 2019-09-13
MX2019008993A (es) 2019-12-19
PE20191479A1 (es) 2019-10-16
CA3051034A1 (en) 2018-08-09
US11376241B2 (en) 2022-07-05
CR20190393A (es) 2019-10-21
WO2018141855A1 (en) 2018-08-09
CO2019007882A2 (es) 2019-10-09
UY37590A (es) 2018-02-28
EA201991600A1 (ru) 2020-03-10
PH12019550136A1 (en) 2020-03-02
SG11201906959RA (en) 2019-08-27
AR110790A1 (es) 2019-05-02
US20210260045A1 (en) 2021-08-26
BR112019015704A2 (pt) 2020-04-07
NI201900075A (es) 2019-10-30
AU2018216955A1 (en) 2019-08-01
KR20190113902A (ko) 2019-10-08
TWI674260B (zh) 2019-10-11
TW201838991A (zh) 2018-11-01
IL268082A (en) 2019-09-26

Similar Documents

Publication Publication Date Title
CL2019002314A1 (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr).
CL2019002108A1 (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr).
CL2019002112A1 (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr).
CL2019003015A1 (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
CL2018002505A1 (es) Inhibidores del envejecimiento proteico-proteico wdr5
CL2018002467A1 (es) El uso de moduladores de receptores de glucocorticoides para potenciar los inhibidores de checkpoint
GT201600215A (es) Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4
CL2016000341A1 (es) Métodos para tratar la miositis por cuerpos de inclusión esporádica
NI201800075A (es) Derivados de tiohidantoína sustituidos como antagonistas del receptor de andrógenos.
MX2020004519A (es) Moduladores de la vía de estrés integrada.
CO7160047A2 (es) Compuestos y composiciones que modulan la actividad del receptor del factor de crecimiento epidérmico (egfr)
UY36068A (es) INHIBIDORES DE TGF-ß Y MÉTODOS DE USO
ECSP20018487A (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
ECSP17038999A (es) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
UY35993A (es) Prolinas / piperidinas sustituidas como antagonistas del receptor de orexina
CO2017004074A2 (es) Derivados de benzotiofenilo sustituido como agonistas de gpr40 para el tratamiento de la diabetes tipo ii
CO2017011017A2 (es) Azabenzimidazoles y su uso como moduladores del receptor ampa
DOP2016000212A (es) Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
UY36209A (es) Derivados de la pirazina como agonistas moduladores del receptor gpr40 y composiciones farmacéuticas que los contienen
CL2016000325A1 (es) Antagonistas de vía para tratar trastornos del sueño por cambio de fase
ECSP16074207A (es) Pirazinas moduladoras de gpr6
GT201600255A (es) Compuestos, composición farmacéutica y su uso para tratar enfermedades neurodegenerativas